FXYD domain containing ion transport regulator 5Genealiases: DYSAD · HSPC113 · IWU1 · KCT1 · OIT2 · PRO6241
Q-omics provides the consensus-scored FXYD5 profile across patient tissues and cancer cell-line models. FXYD5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FXYD5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FXYD5 RNA expression shows 17,958 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where FXYD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FXYD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FXYD5 survival associations across molecular data types. FXYD5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FXYD5 RNA expression–survival associations across cancer types. High FXYD5 expression shows unfavorable associations in KIRC, MESO, OV, HNSC, UVM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FXYD5 RNA expression.
This table summarizes FXYD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FXYD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FXYD5 shows higher tumor expression in HNSC, COAD, THCA, KIRC, STAD and READ. The HNSC box plot shows higher FXYD5 RNA expression in tumor versus normal tissue (log2 FC = +2.638, t-test p < 0.001).
This table shows molecular features associated with FXYD5 in patient tissues and cancer cell lines. In patient samples, FXYD5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FXYD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
